.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Argus Health
Daiichi Sankyo
QuintilesIMS
Dow
Harvard Business School
Moodys
US Army
McKinsey

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203313

« Back to Dashboard
NDA 203313 describes RYZODEG 70/30, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are eleven patents protecting this drug. Additional details are available on the RYZODEG 70/30 profile page.

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are thirty-eight drug master file entries for this compound. Additional details are available on the insulin aspart; insulin degludec profile page.

Summary for NDA: 203313

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)
Approval Date:Sep 25, 2015TE:RLD:Yes
Patent:5,866,538Patent Expiration:Jun 20, 2017Product Flag?YSubstance Flag?Delist Request?
Patent:6,899,699Patent Expiration:Jan 2, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:7,615,532Patent Expiration:May 25, 2025Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 203313

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc
RYZODEG 70/30
insulin aspart; insulin degludec
SOLUTION;SUBCUTANEOUS203313-001Sep 25, 20155,866,538► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Accenture
Mallinckrodt
Colorcon
Johnson and Johnson
Chubb
Julphar
Covington
US Department of Justice
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot